Bronchitis

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

Retrieved on: 
onsdag, maj 22, 2024
ATP, ACL, Risk, Molina Healthcare, Ageing, Agent handling, Adverse event, CVD, Esperion Therapeutics, Back pain, Angioedema, Cholesterol, Gout, Kidney, Constipation, Treatment, Civil service commission, European Commission, Fetus, Anaphylaxis, Hypersensitivity, Moyamoya disease, Bempedoic acid, Urinary tract infection, Anemia, Hypercholesterolemia, Upper respiratory tract infection, Safety, Ezetimibe, CLEAR, Incidence, Bronchitis, Excipient, Diet, Gallstone, Rash, Patient, Cardiovascular disease, Diarrhea, Abdominal pain, Uric acid, Spasm, University, University of Milan, Therapy, Arthralgia, Sinusitis, Pregnancy, European, Stroke, Health, Common, Death, FDC, Fatigue, Myocardial infarction, Tablet, Rupture, Pain, CHMP, Dietary supplement

ANN ARBOR, Mich. and MUNICH, Germany, May 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics, Inc. jointly announced today that the European Commission (EC) has approved the label update of both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination (FDC)), as treatments for hypercholesterolemia (high levels of cholesterol) and to reduce the risk of adverse cardiovascular events. The EC’s decisions to update the labels of bempedoic acid and bempedoic acid / ezetimibe FDC are based on the positive CLEAR Outcomes trial results and makes them the first and only LDL-C lowering treatments indicated for primary and secondary prevention of cardiovascular events.

Key Points: 
  • Bempedoic acid is a first-in-class oral treatment which lowers cholesterol, and which can be combined with other treatments to help lower cholesterol even further.
  • Bempedoic acid provided additional cholesterol lowering of up to 28% on top of statin therapy, compared to placebo.
  • “Today's announcement marks a pivotal moment in our ongoing efforts to reduce cardiovascular risk.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease

Retrieved on: 
söndag, maj 19, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Patient, Lung, AMG, Rheumatology, Biopharmaceutical, Immunology, Risk, Heart, Allergy, Conditional sentence, Disease, Safety, Asthma, Bronchitis, Tezepelumab, Dermatology, Hospital, Death, Growth, TSLP, Eosinophilic, COPD, Emphysema, Chronic obstructive pulmonary disease, Mortality, Inflammation, AstraZeneca, Gastroenterology, Pharmaceutical industry

Patients received tezepelumab 420 mg, or placebo, administered via subcutaneous injection at the trial site every four weeks over a 52-week treatment period.

Key Points: 
  • Patients received tezepelumab 420 mg, or placebo, administered via subcutaneous injection at the trial site every four weeks over a 52-week treatment period.
  • Both companies will continue to share costs and profits equally after payment by AstraZeneca of a mid single-digit inventor royalty to Amgen.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Saving Cell Therapy

Retrieved on: 
onsdag, maj 8, 2024
NMDP, Blood, Life saver, Publicis, Bronchitis, Research, Leukemia, Patient, American Symphony, Bone marrow, Acute myeloid leukemia, Higher Ground, Cipriani S.A., AstraZeneca, Pharmaceutical industry

In 2023, NMDP provided $5.5 million in grants to 2,600 patients and their families in need of financial assistance.

Key Points: 
  • In 2023, NMDP provided $5.5 million in grants to 2,600 patients and their families in need of financial assistance.
  • The event’s presenting sponsor, Publicis Groupe and Publicis Media, continued their long-standing support of NMDP.
  • “All of us at NMDP are honored to witness meetings like Lisa and Eric’s” said Joy King, Chief Advancement Officer, NMDP.
  • The organization recently unveiled breakthrough research that will allow more patients with blood cancer or blood disorders to receive life-saving cell therapy.

Monteloeder's Award-Winning Lemon Verbena Enters into a Quest of Discovery at Hub De La Vera

Retrieved on: 
tisdag, maj 7, 2024
Humidity, Mineral, Triterpene, Pesticide, Health, Bronchitis, Tobacco, Research, Vitamin, Fertilizer, Aloysia citrodora, Carbon, Herb, Farmer, Liver disease, Flavonoid, Soil, Nutrient, Temperature, Nutraceutical, Technical

MADRID, May 7, 2024 /PRNewswire/ -- Nutraceuticals leader Monteloeder, S.L., a subsidiary of SUANNUTRA, is participating in La Vera Campo Arañuelo Hub, a visionary project that will bring cultivation and production of its flagship botanical lemon verbena (Aloysia citrodora) to Cáceres, Spain. There, it will serve as a keystone ingredient for research and agricultural innovation and will replace tobacco plants. Monteloeder will highlight lemon verbena as a core constituent of its bioactive ingredient portfolio at Vitafoods Europe in Geneva, 14-16 May.

Key Points: 
  • Monteloeder will highlight lemon verbena as a core constituent of its bioactive ingredient portfolio at Vitafoods Europe in Geneva, 14-16 May.
  • "Lemon verbena is naturally graced with a versatile spectrum of beneficial traits," explains Maria Ángeles Gutiérrez Marketing Director of SUANNUTRA.
  • Monteloeder is one of seven companies taking part in the La Vera Campo Arañuelo Hub agronomical research campaign.
  • The lemon verbena will grow alongside 14 other botanical crops, including sage, hops, and lemon balm.

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024

Retrieved on: 
onsdag, maj 1, 2024
AMGN, MPA, Effectiveness, Political moderate, Prednisone, ATS, Chronic obstructive pulmonary disease, Emphysema, Polyp (medicine), Inflammation, Hospital, Exercise, ANCA, Post hoc analysis, Abstract, PDT, Research and development, Biomarker, Initiation, Conference, Development, Literature, Vasculitis, History, GPA, Clinical, Amgen, Bronchitis, COPD, Pharmaceutical industry

THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.

Key Points: 
  • THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego.
  • Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.
  • "Our efforts underscore Amgen's commitment to pioneering new treatments for respiratory diseases with currently limited treatment options."
  • Data from the COURSE trial will be presented within the Clinical Trials Symposium.

Incannex Healthcare Inc. Quarterly Update, Q1 2024

Retrieved on: 
tisdag, april 16, 2024
FDA, Psilocybin, Pregabalin, Risk, Obstruction, Phase II, IND, NCT, GAD, Serotonin, Biomarker, Sleep, Deficit spending, Inflammation, Benzodiazepine, Pharmacokinetics, Food, HCQ, IRB, Psychotherapy, Diazepam, Quality of life, OSA, Food and Drug Administration, Pain, Patient, Somnolence, Institutional review board, Safety, Tissue, Bronchitis, PRO, Research, Monash University, Joint, Fatigue, EMA, Dronabinol, PAP, Clinical trial, Asthma, AHI, Accident, COPD, Acetazolamide, NDA, Rheumatoid arthritis, Colitis, Joint stiffness, Obstructive sleep apnea, CBD, Disease, Inflammatory bowel disease, Sleep apnea, Hydroxychloroquine, Cannabidiol, Pharmaceutical industry

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
  • Incannex is undertaking various U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.
  • During the quarter, Incannex released top line results from the PsiGAD1 clinical trial conducted at Monash University, based in Melbourne, Australia.
  • This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
onsdag, maj 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis

Retrieved on: 
tisdag, april 30, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hemoptysis, MCID, Inflammation, Safety, Mucus, QOL, Professor, Bronchiectasis, MD, Doctor of Philosophy, Conference, Mycobacterium, Sputum, Periodic breathing, Urinary tract infection, CAAT, Disease, Chronic cough, Patient, Principal, Aes, Diagnosis, Inc., ITT, American Thoracic Society, Quality of life, Asthma, Bronchitis, National Jewish Health, Division, Infection, COPD, Pharmaceutical industry

The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.

Key Points: 
  • The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.
  • Participants were randomized (7:3, treatment:placebo), and 40 participants completed the study, with 29 completing in the ARINA-1 arm and 11 in the placebo (0.9% saline) arm.
  • Topline results from the intention-to-treat (ITT) population demonstrate that ARINA-1 is safe and improves quality of life (QOL) in individuals with NCFBE who experience mucus symptoms.
  • Renovion will discuss study results at the American Thoracic Society Meeting (May 17-22) and present findings at the World Bronchiectasis Conference (July 4-6) in Dundee, Scotland.

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Retrieved on: 
tisdag, april 16, 2024
Fetus, AMGN, American Thoracic Society, Congress, Arthralgia, ATS, Chronic obstructive pulmonary disease, Emphysema, Pregnancy, Infection, Tezepelumab, PDT, Allergic conjunctivitis, Amgen, Research and development, Back pain, Conference, Placentalia, Vaccine, Miscarriage, Development, Ageing, Helminthiasis, Incidence, Patient, Anaphylaxis, Hypersensitivity, Rash, Pharyngitis, Birth, Asthma, Bronchitis, AstraZeneca, Excipient, Pharmaceutical industry

THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. 

Key Points: 
  • Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17% (90% CI: −6, 36; p=0.1042).
  • Of note, more reductions were observed in a prespecified subgroup of patients with BEC ≥150 cells/μL (37% [95% CI: 7, 57]).
  • The trend in reduction was greater in a small number of subjects with BEC ≥300 cells/µL.
  • We look forward to presenting the full data set at the congress and based on these findings, we are actively planning for the Phase 3 development of tezepelumab in COPD.

Herbal medicinal product: Eucalypti aetheroleumArray,Array,Array, F: Assessment finalised

Retrieved on: 
torsdag, april 18, 2024
Eucalyptus oil, Bronchitis, Spasm, Seizure, System, Risk, Inflammation, Patient, Lung, Monograph, Committee, Inhalation, Steam, Herbal medicine, Date, Asthma, Heart failure, Plant, Mouth, Infection, Skin, Fever, Myalgia, Water, Larynx, Medicine, Dietary supplement

Herbal medicinal product: Eucalypti aetheroleumArray,Array,Array, F: Assessment finalised

Key Points: 


Herbal medicinal product: Eucalypti aetheroleumArray,Array,Array, F: Assessment finalised